https://mindmedicinelaw.com/briefing/improving-psychedelic-clinical-trials-methodology-challenges-and-next-steps-20260916-42463The Psychedelic Journalen2026-09-16T22:07:22.935633+00:00Improving Psychedelic Clinical Trials: Methodology Challenges and Next Stepspsychedelic clinical trials, blinding in trials, expectancy effects, trial reproducibility, FDA guidance, regulatory standards, methodological rigor, psychedelic research, clinical trial design, public health policyhttps://mindmedicinelaw.com/briefing/fda-poised-to-approve-psychedelic-therapy-for-trd-implications-and-next-steps-20260916-42462The Psychedelic Journalen2026-09-16T22:05:27.144886+00:00FDA Poised to Approve Psychedelic Therapy for TRD: Implications and Next Stepsfda approval, psilocybin therapy, treatment-resistant depression, compass pathways, clinical trials, policy implications, insurance coverage, psychedelic medicine, risk evaluation, mental health innovationhttps://mindmedicinelaw.com/briefing/fda-revisits-psychedelic-regulation-implications-for-us-policy-20260916-42304The Psychedelic Journalen2026-09-16T15:05:41.303987+00:00FDA Revisits Psychedelic Regulation: Implications for US Policyfda psychedelic regulation, psychedelic clinical trials, us drug policy, mdma approval process, psilocybin research, controlled substances act, real-world evidence, clinical trial design, patient access, regulatory riskhttps://mindmedicinelaw.com/briefing/fda-psychedelics-hearing-regulatory-pathways-and-policy-signals-2026-20260916-42306The Psychedelic Journalen2026-09-16T15:05:17.605504+00:00FDA Psychedelics Hearing: Regulatory Pathways and Policy Signals (2026)fda psychedelics hearing, psychedelic therapy regulation, clinical trial design, controlled substances act, risk evaluation and mitigation strategies, drug approval pathways, public health policy, market access, real-world evidence, post-approval controlshttps://mindmedicinelaw.com/briefing/fda-public-hearing-on-psychedelics-u-s-policy-at-a-crossroads-20260916-42307The Psychedelic Journalen2026-09-16T15:04:51.155495+00:00FDA Public Hearing on Psychedelics: U.S. Policy at a Crossroadsfda public hearing, psychedelic policy, trump administration, drug rescheduling, clinical research access, industry investment, regulatory risk, insurance reimbursement, us drug law, controlled substances acthttps://mindmedicinelaw.com/briefing/fda-faces-scrutiny-after-death-and-misconduct-in-psychedelic-care-20260916-42305The Psychedelic Journalen2026-09-16T15:04:28.149171+00:00FDA Faces Scrutiny After Death and Misconduct in Psychedelic Carefda, psychedelic-assisted therapy, patient safety, provider misconduct, clinical trial risk, regulatory policy, mdma, psilocybin, adverse events, risk managementhttps://mindmedicinelaw.com/briefing/music-as-a-contextual-variable-in-psychedelic-therapy-trials-20260915-42351The Psychedelic Journalen2026-09-16T22:07:45.991429+00:00Music as a Contextual Variable in Psychedelic Therapy Trialspsychedelic-assisted psychotherapy, music in therapy, clinical trial design, contextual factors, complex interventions, regulatory standards, trial reproducibility, adverse events, functional standardizationhttps://mindmedicinelaw.com/briefing/neurocognitive-model-psychedelics-and-hippocampal-reset-in-anxiety-relief-20260915-42350The Psychedelic Journalen2026-09-16T22:06:42.669265+00:00Neurocognitive Model: Psychedelics and Hippocampal Reset in Anxiety Reliefpsychedelics, anxiety disorders, hippocampal reset, neurocognitive model, psilocybin, clinical trial design, biomarkers, cortical plasticity, regulatory policyhttps://mindmedicinelaw.com/briefing/lived-experience-as-evidence-in-psychedelic-public-health-policy-20260915-42352The Psychedelic Journalen2026-09-16T22:06:26.065111+00:00Lived Experience as Evidence in Psychedelic Public Health Policylived experience, psychedelic public health, clinical trials, policy development, aftercare, systems-relevant evidence, regulatory oversight, patient safety, program evaluationhttps://mindmedicinelaw.com/briefing/psilocybin-ayahuasca-for-trd-evidence-ethics-and-research-gaps-20260915-42353The Psychedelic Journalen2026-09-16T22:06:05.582463+00:00Psilocybin & Ayahuasca for TRD: Evidence, Ethics, and Research Gapspsilocybin, ayahuasca, treatment-resistant depression, clinical trial design, ethical challenges, blinding, informed consent, psychedelic-assisted therapy, regulatory science, methodological limitationshttps://mindmedicinelaw.com/briefing/compass-pathways-psilocybin-durability-data-implications-for-u-s-depression-trea-20260915-42146The Psychedelic Journalen2026-09-15T22:03:58.271298+00:00Compass Pathways’ Psilocybin Durability Data: Implications for U.S. Depression Treatment Policypsilocybin, compass pathways, depression, durability, fda approval, clinical trial, payer coverage, mental health, psychedelic therapy, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/usc-launches-clinical-study-on-meditation-in-psychedelic-therapy-20260915-41984The Psychedelic Journalen2026-09-15T15:07:16.895705+00:00USC Launches Clinical Study on Meditation in Psychedelic Therapyusc psychedelic trial, meditation and psychedelics, clinical protocols, set and setting, therapist training, psychedelic-assisted therapy, integration practices, clinical trial design, adverse events, regulatory implicationshttps://mindmedicinelaw.com/briefing/fda-s-2026-hearing-sets-new-standards-for-psychedelic-therapies-20260915-41981The Psychedelic Journalen2026-09-15T15:06:10.509785+00:00FDA’s 2026 Hearing Sets New Standards for Psychedelic Therapiesfda psychedelic standards, psychedelic therapy regulation, clinical trial requirements, mdma psilocybin lsd, therapist training standards, drug approval process, public health policy, market access psychedelics, post-market surveillancehttps://mindmedicinelaw.com/briefing/fda-issues-regulatory-framework-for-psychedelic-drug-sponsors-20260915-41982The Psychedelic Journalen2026-09-15T15:05:53.660749+00:00FDA Issues Regulatory Framework for Psychedelic Drug Sponsorsfda psychedelic framework, psychedelic clinical trials, drug approval process, therapist training requirements, safety monitoring psychedelics, policy implications psychedelics, psychedelic research compliance, mdma psilocybin regulationhttps://mindmedicinelaw.com/briefing/prenatal-dexamethasone-and-neurogenesis-epigenetic-risks-in-psychiatric-health-20260914-42390The Psychedelic Journalen2026-09-16T22:08:30.483853+00:00Prenatal Dexamethasone and Neurogenesis: Epigenetic Risks in Psychiatric Healthprenatal dexamethasone, hippocampal neurogenesis, epigenetic regulation, psychiatric risk, glucocorticoid exposure, PI3K-Akt-mTOR pathway, psychedelic therapy, depression-like behaviors, neurodevelopment, public health policyhttps://mindmedicinelaw.com/briefing/pharmacogenetics-and-psychotropic-response-implications-for-psychedelic-psychiat-20260914-42399The Psychedelic Journalen2026-09-16T22:08:07.882523+00:00Pharmacogenetics and Psychotropic Response: Implications for Psychedelic Psychiatrypharmacogenetics, cyp2d6, cyp2c19, psychedelic therapy, personalized medicine, clinical trial design, phenoconversion, adverse events, precision psychiatryhttps://mindmedicinelaw.com/briefing/5-ht2a-receptor-mechanisms-and-policy-implications-in-psychedelic-research-20260914-42354The Psychedelic Journalen2026-09-16T22:07:02.123784+00:005-HT2A Receptor: Mechanisms and Policy Implications in Psychedelic Research5-ht2a receptor, psychedelics, mechanism of action, neuroplasticity, clinical trials, mental disorders, policy implications, biomarkers, regulatory sciencehttps://mindmedicinelaw.com/briefing/fda-hears-veterans-perspectives-on-psychedelic-ptsd-therapy-20260914-41983The Psychedelic Journalen2026-09-15T15:07:03.695020+00:00FDA Hears Veterans' Perspectives on Psychedelic PTSD Therapyfda hearing, veterans, psychedelic therapy, ptsd treatment, mdma, psilocybin, policy, clinical trials, patient testimony, regulatory processhttps://mindmedicinelaw.com/briefing/us-fda-psychedelic-approvals-impacts-on-japanese-pharmacy-policy-20260913-41867The Psychedelic Journalen2026-09-15T15:06:44.957854+00:00US FDA Psychedelic Approvals: Impacts on Japanese Pharmacy Policyus fda psychedelic approval, japan pharmacy policy, ibogaine regulation japan, pmda drug scheduling, cyp2d6 pharmacogenomics, psychedelic counseling japan, treatment-resistant depression, drug interaction management, international regulatory pressurehttps://mindmedicinelaw.com/briefing/fda-withholds-approval-phase-3-psilocybin-mdma-trials-in-us-psychiatry-20260913-41905The Psychedelic Journalen2026-09-15T15:06:27.497722+00:00FDA Withholds Approval: Phase 3 Psilocybin, MDMA Trials in US Psychiatrypsilocybin phase 3 trial, mdma fda rejection, psychedelic-assisted therapy, clinical trial methodology, psychiatric drug approval, depression treatment research, ptsd clinical trials, regulatory policy, long-term safety, therapist training standardshttps://mindmedicinelaw.com/briefing/structured-at-home-ketamine-protocol-clinical-and-policy-implications-20260911-42395The Psychedelic Journalen2026-09-16T22:05:45.663309+00:00Structured At-Home Ketamine Protocol: Clinical and Policy Implicationsat-home ketamine, racemic ketamine protocol, psychiatric treatment, decentralized therapy, route-specific dosing, telemedicine, regulatory standards, patient safety, clinical best practiceshttps://mindmedicinelaw.com/briefing/suicidality-in-psychosis-risk-youth-depression-not-psychosis-drives-risk-20260911-41868The Psychedelic Journalen2026-09-15T15:07:35.473903+00:00Suicidality in Psychosis-Risk Youth: Depression, Not Psychosis, Drives Risksuicidal ideation, psychosis risk, depression, cannabis use, clinical trials, youth mental health, psychedelic research, public health policy, socio-occupational functioning